Table 3.

Adherence to treatment guidelines and blood pressure control in previous studies compared with the present study

Country	Year	Study population	Population sampling	Number of patients	Guideline lipid-lowering therapy prescription,^a %	Guideline antihypertensive prescription,^a %	Controlled blood pressure
Belgium10	2010	High risk^b	Selected sample from multiple centres	11 069	80	68	13
Italy11	2006	High risk^b	Random sample from multiple centres	3120	56	70	28
Italy12	2010	High risk^b	Random sample from multiple centres	5731	–	67	–
Switzerland13	2010	High risk^b	Entire population from study area	23 892	71	77	62
^cEurope14	2010	Primary prevention	Patients attending study clinic	4366	50	86	29
Canada15	2012	High risk^b	Entire population from study area	4931	–	94	50
UK: present study	2014	Primary prevention	Entire population from study area	12 349	80	88	56
UK: present study	2014	Secondary prevention	Entire population from study area	2550	74	91	62

↵a Medication prescriptions in those eligible for treatment (according to relevant guidelines).
↵b Existing cardiovascular disease or high risk because of existence of diabetes, chronic kidney disease or >20% cardiovascular risk score.
↵c Belgium (n = 106), Bulgaria (n = 327), Croatia (n = 398), Finland (n = 518), Germany (n = 206), Italy (n = 548), Latvia (n = 321), Poland (n = 394), Romania (n = 485), Slovenia (n = 163), Spain (n = 519), UK (n = 381).